Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.
about
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsThe two faces of miR-29Clinical Advancements in the Targeted Therapies against Liver Fibrosis.Regulation of cardiac expression of the diabetic marker microRNA miR-29Autophagy and cartilage homeostasis mechanisms in joint health, aging and OAChronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyCytopenia and autoimmune diseases: a vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells.Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation stabilizes ISCU protein: implications for iron metabolism.Peripheral administration of translation inhibitors reverses increased hyperalgesia in a model of chronic pain in the rat.Glucosamine activates autophagy in vitro and in vivo.Autophagy in Diabetic Retinopathy.Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis.Adverse events associated with mTOR inhibitors.Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.mTOR inhibitors and renal allograft: Yin and Yang.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.Postoperative complications associated with perioperative sirolimus prior to pediatric cardiac retransplantation.One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.Cellular and molecular mechanisms of intestinal fibrosis.Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q26823023-311732B9-C821-4ADC-8139-5B66A8A92BD9Q26996481-B7903DE3-0789-419C-8197-0EC3B7723404Q28078684-C0E3FB8A-63A5-4721-A390-3CCBF0A56180Q28541217-C327F9D9-68ED-45D2-A02B-EDC8AA16CD4EQ35335855-D392A938-6BBF-4E9E-9476-022B9977BCBBQ35758129-7498EF25-161B-4ED5-8AEB-CE99162FBF93Q35911227-0EE0F1CE-435A-4D34-8FFE-B94EA270B036Q36722548-9120021A-BC22-47D0-A2F5-86BBB5DCE018Q36756168-63747B60-50E2-4CCE-8ECA-98CA3B3CE47BQ36812444-43FC8CE8-6EA3-4F3A-9DB7-98ADC7FEE953Q36979846-55BFC1B3-768E-4A3F-A2EC-EE5139C635FDQ37168084-F8838682-49AA-4F99-8810-08F72438C356Q37677015-EA194664-09DE-455E-855F-73CADC5E9C6CQ37947984-F77A2FA2-A49C-47C3-9BBA-562D6BD7D706Q38028872-E8E7216D-A974-4341-80B2-72D4EF5D6EE1Q38068519-1DFDA4F0-83E4-41FA-AD61-4D78C6B855A4Q38187197-104E6689-EC48-479F-BA42-82EE5AAF5D06Q38209973-FECCEB9A-4526-465D-ACC5-CC0A2177BBADQ38895113-23D60BF1-A6B4-4520-8A51-5A0086D05DC5Q38954484-E6852F15-9491-46CC-90BB-52525E915D93Q41429564-406CFCE4-B883-417E-95CA-EED114DF9CFFQ42252132-C2E504B2-5891-4C03-8DEB-DCA6A8D634C8Q45150840-2E072120-285E-45DD-A0F7-CBD27B996957Q47867384-76DDC451-6752-4D31-B9D3-FA40414DF710Q51189916-51A40388-65C1-48A2-8F14-9504FAB0B33EQ58805821-60D6D0EE-0678-454F-9CEF-F94A18BACE31
P2860
Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mammalian target of rapamycin ...... aematological adverse effects.
@ast
Mammalian target of rapamycin ...... aematological adverse effects.
@en
type
label
Mammalian target of rapamycin ...... aematological adverse effects.
@ast
Mammalian target of rapamycin ...... aematological adverse effects.
@en
prefLabel
Mammalian target of rapamycin ...... aematological adverse effects.
@ast
Mammalian target of rapamycin ...... aematological adverse effects.
@en
P2860
P1433
P1476
Mammalian target of rapamycin ...... aematological adverse effects.
@en
P2093
David Goldsmith
Sofia Sofroniadou
P2860
P304
P356
10.2165/11585040-000000000-00000
P577
2011-02-01T00:00:00Z
P6179
1027638001